Instead, in the broader sample not restricted by PD-L1 expression included in the Lung Cancer Mutation Consortium study, 27% of 1655 patients had metastatic lung adenocarcinomas harboring a KRAS mutation [8]. This evidence concerns the gene CD274 and lung carcinoma.